QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS

QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS

Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BARBOUR, PATRICK MICHAEL, TARLTON, EUGENE, BROWN, KATIE KEATON, KAHN, DEAN RUSSELL, PRIGARO, BRETT JOSEPH, REN, LI, HICKEN, ERIK JAMES, MORENO, DAVID AUSTIN, NEWHOUSE, BRADLEY JON, METCALF, ANDREW TERRANCE, PAJK, SPENCER PHILLIP, LAIRD, ELLEN RUTH, COOK, ADAM WADE
Format: Patent
Sprache:eng ; fre
Schlagworte:
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors. L'invention concerne des composés de Formule I : et des sels, solvats et polymorphes pharmaceutiquement acceptables de ceux-ci, dans laquelle L, X1, R1, R2, R3, R4, R5 et R6 sont tels que définis dans la description, pour le traitement de maladies et de troubles associés à BRAF, notamment des tumeurs associées à BRAF, comprenant des tumeurs malignes et bénignes du SNC associées à BRAF et des tumeurs malignes extracraniennes associées à BRAF.